Clinical Trial Update: Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 results evaluating the efficacy, safety, and tolerability of TC-5619 as augmentation therapy for negative symptoms and cognitive dysfunction in outpatie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• TC-5619

Snippet

Sponsor: Targacept Inc. | Conditions: Schizophrenia, Negative Symptoms | Phase 2 | Status: COMPLETED